Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB

5 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Treatments and conditions

Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB
Treatment and conditionWhere it standsTrials
Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for adenocarcinoma, papillaryPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for carcinoma, basosquamousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for carcinoma, signet ring cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for eccrine porocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for paget disease, extramammaryPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1